Corona Remedies Ltd

Corona Remedies Capital Structure Change

Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,629,880 equity shares of Corona Remedies Limited. This non-promoter stake sale is disclosed under SEBI SAST regulations.

Corona Remedies Price Movement Clarification

CORONA Remedies Limited clarified that the recent increase in its share trading volume is purely market-driven and no undisclosed price-sensitive information exists.

Corona Remedies Earnings Call Transcript: Key Takeaways

Corona Remedies reported robust Q1 FY27 results with 21.9% revenue growth and 33.5% EBITDA growth. Strategy focuses on chronic therapies and scaling brand portfolios.

Call

Guides 20% growth

Corona Remedies Investor Presentation: Key Takeaways

Corona Remedies reported strong Q1FY27 performance with 21.9% revenue growth and 33.5% EBITDA growth, driven by its strategic shift towards chronic therapies which now contribute ~73.4% of revenue.

Corona Remedies Results Update

CORONA Remedies reported Q1FY27 Revenue of ₹422.4 Crore, up 21.9% Y-o-Y, and PAT of ₹60.1 Crore, up 30.1% Y-o-Y, highlighting resilient growth.

Corona Remedies Q1 FY27 Results: Net Profit ₹60.1 Cr, Up 30.1% YoY

Corona Remedies Ltd reported revenue from operations of ₹422.4 Cr (+21.9% YoY) and net profit of ₹60.1 Cr (+30.1% YoY) for Q1 FY27.

Key figure

Net profit ₹60.1 Cr · +30.1% YoY

Corona Remedies Board Meeting Date

Corona Remedies scheduled a board meeting on July 31, 2026. The board will consider unaudited quarterly financial results for the period ended June 30, 2026.

Corona Remedies Annual General Meeting

CORONA Remedies Limited held its 22nd AGM on July 9, 2026, approving a final dividend of ₹10 per share. The meeting also appointed directors and auditors.